Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8071 to 8085 of 8904 results

  1. Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

    This guidance has been updated and replaced by NICE technology appraisal guidance 653.

    Withdrawn guidance

  2. Human growth hormone for the treatment growth failure in children (TA42)

    This guidance has been updated and replaced by NICE technology appraisal guidance 188. 

    Withdrawn guidance

  3. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

    This guidance has been updated and replaced by NICE technology appraisal guidance 795.

    Withdrawn guidance

  4. Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

    This guidance has been updated and replaced by NICE technology appraisal guidance 739.

    Withdrawn guidance

  5. Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

    This guidance has been updated and replaced by NICE technology appraisal guidance 616.

    Withdrawn guidance

  6. Liquid-based cytology for cervical screening (TA5)

    This guidance has been replaced by NICE technology appraisal guidance 69.

    Withdrawn guidance

  7. Imanitib for chronic myeloid leukaemia (TA50)

    This guidance has been updated and replaced by NICE technology appraisal guidance 70 [Partially updated by NICE technology appraisal guidance 241].

    Withdrawn guidance

  8. Carfilzomib for previously treated multiple myeloma (TA457)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 657 

    Withdrawn guidance

  9. Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

    We have withdrawn the guidance because collagenase clostridium histolyticum (Xiapex) is no longer available in the UK.

    Withdrawn guidance

  10. The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)

    This guidance has been updated and replaced by NICE guideline CG43.

    Withdrawn guidance

  11. Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)

    This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation.

    Withdrawn guidance

  12. Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)

    This advice has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  13. Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

    We have withdrawn this guidance. Allergan has stopped marketing eluxadoline (Truberzi) for commercial reasons and its marketing authorisation has been withdrawn.

    Withdrawn guidance

  14. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA397)

    This guidance has been updated and replaced by NICE technology appraisal guidance 752.

    Withdrawn guidance

  15. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Withdrawn guidance